Endomysial Antibody, IgG
Also known as: EMA IGG
Use
The presence of endomysial antibodies IgG, may be useful in identifying IgA-deficient patients at risk for celiac disease. Positive results from this test must be confirmed through a biopsy of the small intestine to establish a diagnosis of celiac disease. It is noteworthy that IgA deficiency can affect the interpretation of other serological tests, thereby making IgG-based tests valuable in such contexts. As a result, this test aids in identifying individuals who may benefit from further diagnostic evaluation.
Special Instructions
Not provided.
Limitations
This test was developed and performed in a CLIA-certified laboratory, and has been established for clinical purposes. However, the test has not been cleared or approved by the US Food and Drug Administration (FDA). Furthermore, while positive results may suggest celiac disease in IgA-deficient patients, definitive diagnosis requires further confirmation via a biopsy of the small intestine. Therefore, interpretation should be contextualized within comprehensive clinical findings.
New York Approved
Methodology
Immunoassay (Indirect Fluorescent Antibody)
Biomarkers
LOINC Codes
- 51699-7 - Endomysium IgG Titr Ser IF
Result Turnaround Time
1-8 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.15 mL
Container
ARUP Standard Transport Tube
Collection Instructions
Separate serum from cells ASAP or within 2 hours of collection.
Causes for Rejection
Contaminated specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 2 weeks |
| Frozen | 1 year |
Other tests from different labs that may be relevant